Brian Freed, PhD

Brian Freed, PhD, is RheumaGen’s Chief Science Officer, Executive Director of the University of Colorado’s ClinImmune Labs, and the inventor of RheumaGen’s breakthrough HLA gene editing therapy. He is a Professor of Medicine and Immunology at the University of Colorado School of Medicine with more than 35 years of experience in cell and gene therapy and 100+ publications in immunogenetics, biotherapeutics, histocompatibility, transplantation, and stem cell banking. ClinImmune Labs, RheumaGen’s clinical research partner, is a nonprofit biotech company within CU’s School of Medicine. Located at the Anschultz Medical campus, ClinImmune has approximately $20 million in annual revenue, over 90 employees, and 25,000 square feet of state-of-the art lab space, including four cGMP clean rooms. It has 20 active cell therapy trials and has developed two FDA-licensed stem cell therapies.